JW Holdings Corporation (096760.KS)
KRW 3045.0
(0.0%)
KRW 3045.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 143.66 Billion KRW | 39.13% |
| 2022 | 103.25 Billion KRW | 50.24% |
| 2021 | 68.72 Billion KRW | -25.19% |
| 2020 | 91.87 Billion KRW | 3257.76% |
| 2019 | 2.73 Billion KRW | -91.79% |
| 2018 | 33.31 Billion KRW | -19.58% |
| 2017 | 41.42 Billion KRW | -4.44% |
| 2016 | 43.34 Billion KRW | 29.57% |
| 2015 | 33.45 Billion KRW | 42.37% |
| 2014 | 23.5 Billion KRW | 15.09% |
| 2013 | 20.41 Billion KRW | 455.85% |
| 2012 | 3.67 Billion KRW | -40.0% |
| 2011 | 6.12 Billion KRW | -85.14% |
| 2010 | 41.2 Billion KRW | -19.58% |
| 2009 | 51.24 Billion KRW | 12.85% |
| 2008 | 45.4 Billion KRW | 287.64% |
| 2007 | 11.71 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 27.88 Billion KRW | -31.75% |
| 2024 Q1 | 40.85 Billion KRW | -17.06% |
| 2023 Q1 | 33.58 Billion KRW | -18.08% |
| 2023 Q3 | 36.51 Billion KRW | 32.1% |
| 2023 FY | 143.66 Billion KRW | 39.13% |
| 2023 Q4 | 49.26 Billion KRW | 34.92% |
| 2023 Q2 | 27.64 Billion KRW | -17.69% |
| 2022 Q4 | 40.99 Billion KRW | 88.75% |
| 2022 Q2 | 17.08 Billion KRW | -27.15% |
| 2022 FY | 103.25 Billion KRW | 50.24% |
| 2022 Q1 | 23.45 Billion KRW | -12.66% |
| 2022 Q3 | 21.71 Billion KRW | 27.1% |
| 2021 Q4 | 26.85 Billion KRW | 82.36% |
| 2021 FY | 68.72 Billion KRW | -25.19% |
| 2021 Q1 | 20.03 Billion KRW | 29.65% |
| 2021 Q2 | 7.1 Billion KRW | -64.54% |
| 2021 Q3 | 14.72 Billion KRW | 107.28% |
| 2020 Q2 | 3.06 Billion KRW | -63.41% |
| 2020 Q1 | 8.36 Billion KRW | 135.62% |
| 2020 FY | 91.87 Billion KRW | 3257.76% |
| 2020 Q4 | 15.45 Billion KRW | 47.93% |
| 2020 Q3 | 10.44 Billion KRW | 241.26% |
| 2019 Q4 | -23.48 Billion KRW | -270.34% |
| 2019 Q3 | 13.78 Billion KRW | 94.57% |
| 2019 Q2 | 7.08 Billion KRW | 32.5% |
| 2019 Q1 | 5.34 Billion KRW | 155.14% |
| 2019 FY | 2.73 Billion KRW | -91.79% |
| 2018 Q4 | -9.7 Billion KRW | -138.13% |
| 2018 Q1 | 10.05 Billion KRW | 135.17% |
| 2018 FY | 33.31 Billion KRW | -19.58% |
| 2018 Q2 | 7.52 Billion KRW | -25.13% |
| 2018 Q3 | 25.43 Billion KRW | 238.02% |
| 2017 Q3 | 9.96 Billion KRW | -5.55% |
| 2017 FY | 41.42 Billion KRW | -4.44% |
| 2017 Q4 | 4.27 Billion KRW | -57.12% |
| 2017 Q1 | 16.62 Billion KRW | 51.11% |
| 2017 Q2 | 10.55 Billion KRW | -36.54% |
| 2016 Q1 | 12.06 Billion KRW | 48.16% |
| 2016 Q2 | 13.5 Billion KRW | 11.92% |
| 2016 Q3 | 10.14 Billion KRW | -24.86% |
| 2016 FY | 43.34 Billion KRW | 29.57% |
| 2016 Q4 | 11 Billion KRW | 8.49% |
| 2015 FY | 33.45 Billion KRW | 42.37% |
| 2015 Q4 | 8.14 Billion KRW | 5.93% |
| 2015 Q2 | 9.9 Billion KRW | 32.41% |
| 2015 Q1 | 7.48 Billion KRW | 30.56% |
| 2015 Q3 | 7.68 Billion KRW | -22.41% |
| 2014 Q3 | 10.54 Billion KRW | 1111.31% |
| 2014 Q2 | 870.44 Million KRW | -85.16% |
| 2014 Q1 | 5.86 Billion KRW | 80.83% |
| 2014 FY | 23.5 Billion KRW | 15.09% |
| 2014 Q4 | 5.73 Billion KRW | -45.65% |
| 2013 Q1 | 7.14 Billion KRW | 170.45% |
| 2013 Q3 | 5.91 Billion KRW | 79.04% |
| 2013 Q4 | 3.24 Billion KRW | -45.2% |
| 2013 FY | 20.41 Billion KRW | 455.85% |
| 2013 Q2 | 3.3 Billion KRW | -53.74% |
| 2012 Q4 | 2.64 Billion KRW | -46.56% |
| 2012 Q2 | 291.79 Million KRW | 104.87% |
| 2012 Q1 | -5.99 Billion KRW | 0.0% |
| 2012 FY | 3.67 Billion KRW | -40.0% |
| 2012 Q3 | 4.94 Billion KRW | 1594.68% |
| 2011 Q4 | - KRW | 100.0% |
| 2011 FY | 6.12 Billion KRW | -85.14% |
| 2011 Q2 | -236.51 Million KRW | -124.65% |
| 2011 Q1 | 959.46 Million KRW | 0.0% |
| 2011 Q3 | -1.42 Billion KRW | -501.24% |
| 2010 Q3 | 398.99 Million KRW | -73.65% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 FY | 41.2 Billion KRW | -19.58% |
| 2010 Q2 | 1.51 Billion KRW | -25.32% |
| 2010 Q1 | 2.02 Billion KRW | 0.0% |
| 2009 FY | 51.24 Billion KRW | 12.85% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 Q3 | 3.67 Billion KRW | 102.82% |
| 2009 Q2 | 1.81 Billion KRW | 602.8% |
| 2009 Q1 | 257.69 Million KRW | 0.0% |
| 2008 FY | 45.4 Billion KRW | 287.64% |
| 2008 Q4 | - KRW | 100.0% |
| 2008 Q2 | 631.08 Million KRW | 116.72% |
| 2008 Q3 | -1.03 Billion KRW | -263.69% |
| 2008 Q1 | -3.77 Billion KRW | 0.0% |
| 2007 FY | 11.71 Billion KRW | 0.0% |
| 2007 Q3 | -2.36 Billion KRW | 0.0% |
| 2007 Q4 | - KRW | 100.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | -39310.349% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | -86.865% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 280.571% |
| HANDOK Inc. | 12.57 Billion KRW | -1042.12% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | 7322.475% |
| Yuhan Corporation | 74.56 Billion KRW | -92.678% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | -1185.198% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | 896.26% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 36.116% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | -4600.999% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -901.123% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | -23988.644% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | -14806.673% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | -431.475% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -39310.349% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | 1952.3% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | -3461.689% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 305.382% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 368.948% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 41.741% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | -43.23% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 403.14% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | -1974.012% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | -2120.132% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | -1545.391% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -39310.349% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | -194.591% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | -7.69% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | -43.23% |
| Yuhan Corporation | 74.56 Billion KRW | -92.678% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | -586.731% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | -4508.507% |
| Suheung Co., Ltd. | 42.99 Billion KRW | -234.145% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | -43.23% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | -601.342% |
| Korea United Pharm Inc. | 54.94 Billion KRW | -161.449% |
| CKD Bio Corp. | -20.15 Billion KRW | 812.89% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | -345.712% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | -467.801% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | -341.706% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 403.14% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | -333.421% |
| Boryung Corporation | 68.26 Billion KRW | -110.446% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | 483.141% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -901.123% |
| JW Lifescience Corporation | 32.09 Billion KRW | -347.674% |